Clinical study of Adjuvant chemotherapy with TS-1 for breast cancer
Phase 2
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000011860
- Lead Sponsor
- Breastopia Namba Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 380
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active double cancer 2) Bilateral (synchronous or asynchronous) breast cancer, inflammatory breast cancer 3) A history of previous treatment with oral 5-fluorouracil derivatives for 2 weeks or longer (Patients who received intravenous 5-fluorouracil can be enrolled.) 4) Serious diarrhea 5) Others, Serious complications 6) Pregnant women, nursing women, or women who want to become pregnant 7) Patients judged to be unsuitable for enrollment in the study by their physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint : disease-free survival
- Secondary Outcome Measures
Name Time Method Secondary endpoint :overall survival, relapse-free survival, relative dose intensity, and safety